Skip to main content
SpringerLink
Log in

Diagnosis and Neuroprotection in Parkinson's Disease

  • Reference work entry
  • First Online:
Book cover Handbook of Neurochemistry and Molecular Neurobiology

  • 477 Accesses

Abstract:

Insidious onset of mild, unspecific vegetative, psychopathological, cognitive and perceptive disturbances with a resulting change of personal behavior often precede the initially intermittend occurring motor symptoms in patients with Parkinson's disease (PD). Thus the current available diagnostic tools and concepts do not enable such an early diagnosis of Parkinson's disease. However they are necessary to perform an effective neuroprotective treatment regimes, since neuronal dopaminergic death is advanced at the clinical treshold of onset of motor symptoms. Treatment of these symptoms should be formed in a more continuous fashion, in order to imitate and provide more physiological conditions of dopaminergic neurotransmission. This delays onset of motor complications, which may be interpreted as a certain neuroprotective effect from the clinical point of view.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 249.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

5-HT:

5-hydroxytryptamine

PD:

Parkinson's disease

References

  • Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. 1986. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 20: 175–193.

    Article  CAS  PubMed  Google Scholar 

  • Ahlskog JE. 2003. Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology 60: 381–389.

    Article  PubMed  Google Scholar 

  • Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, et al. 1999. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 14: 940–946.

    Article  CAS  PubMed  Google Scholar 

  • Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, et al. 2004. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: The modifying effects of estrogen. Am J Epidemiol 160: 977–984.

    Article  PubMed  Google Scholar 

  • Birkmayer W, Danielczyk W, Neumayer E, Riederer P. 1972. The balance of biogenic amines as condition for normal behaviour. J Neural Transm 33: 163–178.

    Article  CAS  PubMed  Google Scholar 

  • Braak H, Rub U, Gai WP, Del Tredici K. 2003. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517–536.

    Article  CAS  PubMed  Google Scholar 

  • Bryson HM, Milne RJ, Chrisp P. 1992. Selegiline: An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics 2: 118–136.

    Article  CAS  PubMed  Google Scholar 

  • Buhmann C, Glauche V, Sturenburg HJ, Oechsner M, Weiller C, et al. 2003. Pharmacologically modulated fMRI—cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 126: 451–461.

    Article  CAS  PubMed  Google Scholar 

  • Burn DJ. 2002. Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 17: 445–454.

    Article  PubMed  Google Scholar 

  • Clarke CE. 2004a. A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? Mov Disord 19: 491–498.

    Article  PubMed  Google Scholar 

  • Clarke CE. 2004b. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 3: 466–474.

    Article  PubMed  Google Scholar 

  • Clarke CE. 2005. Rasagiline for motor complications in Parkinson's disease. Lancet 365: 914–916.

    Article  PubMed  Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE. 2003. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev CD003467.

    Google Scholar 

  • Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. 2003. Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study. Neurology 60: 601–605.

    Article  CAS  PubMed  Google Scholar 

  • Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, et al. 1999. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 52: 120–125.

    Article  CAS  PubMed  Google Scholar 

  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. 2004. Levodopa and the progression of Parkinson's disease. N Engl J Med 351: 2498–2508.

    Article  CAS  PubMed  Google Scholar 

  • Fearnley JM, Lees AJ. 1990. Striatonigral degeneration. A clinicopathological study. Brain 113 (Pt 6): 1823–1842.

    Article  PubMed  Google Scholar 

  • Foley P, Riederer P. 1999. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 56: 31–74.

    Article  CAS  PubMed  Google Scholar 

  • Fox MJ. 2003. Lucky Man: A Memoir. New York: Hyperion. 2002.

    Google Scholar 

  • Freed CR, Greene PE, Breeze RE, Tsai WY, Du Mouchel W, et al. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344: 710–719.

    Article  CAS  PubMed  Google Scholar 

  • Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, et al. 2001. Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease. Science 293: 1164–1166.

    Article  PubMed  Google Scholar 

  • Fuente-Fernandez R, Schulzer M, Stoessl AJ. 2004. Placebo mechanisms and reward circuitry: Clues from Parkinson's disease. Biol Psychiatry 56: 67–71.

    Article  PubMed  Google Scholar 

  • Gale C, Martyn C. 2003. Tobacco, coffee, and Parkinson's disease. BMJ 326: 561–562.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589–595.

    Article  CAS  PubMed  Google Scholar 

  • Harrower TP, Barker RA. 2004. Is there a future for neural transplantation? BioDrugs 18: 141–153.

    Article  PubMed  Google Scholar 

  • Hauser RA, Hubble JP, Truong DD. 2003. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 61: 297–303.

    Article  CAS  PubMed  Google Scholar 

  • Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. 1995. An essay on Wilhelm von Humboldt and the shaking palsy: First comprehensive description of Parkinson's disease by a patient. Neurology 45: 565–568.

    Article  CAS  PubMed  Google Scholar 

  • Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, et al. 1999. Effect of treatment with l-dopa/carbidopa or l-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT. Mov Disord 14: 436–442.

    Article  CAS  PubMed  Google Scholar 

  • Jankovic J, McDermott M, Carter J, Gauthier S, Goe tz et al. 1990. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology 40: 1529–1534.

    Article  CAS  PubMed  Google Scholar 

  • Jellinger KA, Paulus W. 1992. Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg 94 Suppl: S86–S88.

    Article  PubMed  Google Scholar 

  • Korczyn AD. 1999. Parkinson's disease: One disease entity or many? J Neural Transm Suppl 56: 107–111.

    Article  CAS  PubMed  Google Scholar 

  • Kulisevsky J, Barbanoj M, Gironell A, Antonijoan R, Casas M, et al. 2002. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease. Clin Neuropharmacol 25: 25–31.

    Article  CAS  PubMed  Google Scholar 

  • Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, et al. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661.

    Article  CAS  Google Scholar 

  • Mayeux R. 1990. The “serotonin hypothesis” for depression in Parkinson's disease. Adv Neurol 53: 163–166.

    CAS  PubMed  Google Scholar 

  • Melamed E, Hefti F, Wurtman RJ. 1980. Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism. Ann Neurol 8: 558–563.

    Article  CAS  PubMed  Google Scholar 

  • Morrish P. 2002. Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 17: 229–232.

    Article  PubMed  Google Scholar 

  • Morrish P. 2005. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease. Mov Disord 20: 117–118.

    Article  PubMed  Google Scholar 

  • Morrish PK. 2003a. REAL and CALM: What have we learned? Mov Disord 18: 839–840.

    Article  CAS  PubMed  Google Scholar 

  • Morrish PK. 2003b. The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 1447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morrish PK, Sawle GV, Brooks DJ. 1996. Regional changes in [18F] dopa metabolism in the striatum in Parkinson's disease. Brain (Pt 6): 119 2097–2103.

    Article  PubMed  Google Scholar 

  • Müller T. 2004. Mood disorders in early Parkinson's disease. Curr Opin Psychiatry 17: 191–196.

    Article  Google Scholar 

  • Müller T, Eising EG, Reiners C, Przuntek H, Jacob M, et al. 1997. 2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: Is it a marker of striatal pre-synaptic degeneration? Nucl Med Commun 18: 1115–1121.

    Article  PubMed  Google Scholar 

  • Müller T, Schafer S, Kuhn W, Przuntek H. 2000. Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 27: 311–315.

    Article  PubMed  Google Scholar 

  • Olanow CW, Damier P, Goetz CG, Müller T, Nutt J, et al. 2004. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27: 58–62.

    Article  CAS  PubMed  Google Scholar 

  • Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, et al. 2003. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54: 403–414.

    Article  PubMed  Google Scholar 

  • Parkinson J. 1817. An Essay on the shaking Palsy. London: Sherwood Neely and Jones.

    Google Scholar 

  • Parkinson Study Group 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 328: 176–183.

    Google Scholar 

  • Parkinson Study Group. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661.

    Google Scholar 

  • Parkinson Study Group. 2004. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566.

    Google Scholar 

  • Parkinson Study Group. 2005. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 62: 241–248.

    Google Scholar 

  • Pedata F, Pugliese AM, Melani A, Gianfriddo M. 2003. A2A receptors in neuroprotection of dopaminergic neurons. Neurology 61: S49–S50.

    Article  PubMed  Google Scholar 

  • Peters S, Suchan B, Rusin J, Daum I, Koster O, et al. 2003. Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients. Neuroreport 14: 809–812.

    Article  CAS  PubMed  Google Scholar 

  • Przuntek H, Müller T. 1999. Clinical efficacy of budipine in Parkinson's disease. J Neural Transm Suppl 56: 75–82.

    Article  CAS  PubMed  Google Scholar 

  • Przuntek H, Bittkau S, Bliesath H, Büttner U, Fuchs G, et al. 2002. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59: 803–806.

    Article  PubMed  Google Scholar 

  • Przuntek H, Müller T, Riederer P. 2004. Diagnostic staging of Parkinson's disease: Conceptual aspects. J Neural Transm 111: 201–216.

    Article  CAS  PubMed  Google Scholar 

  • Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, et al. 2005. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomized, double-blind, parallel-group trial. Lancet 365: 947–954.

    Article  CAS  PubMed  Google Scholar 

  • Ross GW, Petrovitch H. 2001. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18: 797–806.

    Article  CAS  PubMed  Google Scholar 

  • Ryoo HL, Pierrotti D, Joyce JN. 1998. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 13: 788–797.

    Article  CAS  PubMed  Google Scholar 

  • Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, et al. 1997. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336: 1216–1222.

    Article  CAS  PubMed  Google Scholar 

  • Schmid G, Suchan B, Rusin J, Daum I, Koster O, et al. 2004. Impact of apomorphine on BOLD signal during movement in normals. J Neural Transm Suppl 68: 69–78.

    Article  Google Scholar 

  • Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, et al. 2000. Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Mov Disord 15: 669–677.

    Article  CAS  PubMed  Google Scholar 

  • Smith LA, Jackson MJ, Al Barghouthy G, Rose S, Kuoppamaki M, et al. 2005. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20: 306–314.

    Article  PubMed  Google Scholar 

  • Stanwood GD, Lucki I, McGonigle P. 2000. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J Pharmacol Exp Ther 295: 1232–1240.

    CAS  PubMed  Google Scholar 

  • Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, et al. 1998. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 13: 29–33.

    Article  CAS  PubMed  Google Scholar 

  • Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, et al. 2003. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: A study in ethnic Chinese. J Neurol Sci 216: 163–167.

    Article  PubMed  Google Scholar 

  • Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, et al. 2004. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75: 141–143.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Torstenson R, Hartvig P, Langstrom B, Bastami S, Antoni G, et al. 1998. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37: 989–995.

    Article  CAS  PubMed  Google Scholar 

  • Uekermann J, Daum I, Peters S, Wiebel B, Przuntek H, et al. 2003. Depressed mood and executive dysfunction in early Parkinson's disease. Acta Neurol Scand 107: 341–348.

    Article  CAS  PubMed  Google Scholar 

  • Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54: 93–101.

    Article  CAS  PubMed  Google Scholar 

  • Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, et al. 2000. Preclinical (premotor) Parkinson's disease. J Neurol 247 Suppl 2: II103–II109.

    PubMed  Google Scholar 

Download references

Authors
  1. T. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Neurochemistry, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, New York, 10962, Orangeburg, USA

    Abel Lajtha (Director) (Director)

  2. Technion‐Rappaport Family Faculty of Medicine, Efron St., POBox 9697, 31096, Haifa, Israel

    Moussa B. H. Youdim (Professor of Pharmacology Professor of Life Sciences Director of Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research) (Professor of Pharmacology Professor of Life Sciences Director of Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research)

  3. Clinic and Policlinic of Psychiatry and Psychotherapy Dept. Clinical Neurochemistry, University of Würzburg, Füchsleinstr. 15, 97080, Würzburg, Germany

    Peter Riederer

  4. Eve Topf Center for Neurodegenerative Diseases Research and Dept. of Pharmacology, Faculty of Medicine Technion, Efron St., P.O.B. 9697, 31096, Haifa, Israel

    Sylvia A. Mandel

  5. Department of Neurosciences, University of Padova Medical School, Via Giustiniani 5, 35128, Padova, Italy

    Leontino Battistin

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this entry

Cite this entry

Müller, T. (2007). Diagnosis and Neuroprotection in Parkinson's Disease. In: Lajtha, A., Youdim, M.B.H., Riederer, P., Mandel, S.A., Battistin, L. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-30377-2_2

Download citation

Publish with us

Policies and ethics

Search

Navigation